4th Quarter - Report

ALSTON & BIRD LLP for BIOMERIEUX, INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Pub. L. No. 119-21, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of US Tax Code. Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
JOSEPH BODDICKER —
ALEXANDER GRAF —
MICHAEL PARK —
MARK RAYDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
ALEXANDER GRAF —
JOYCE E GRESKO —
JONATHAN JAGODA —
JAMES PATRICK PALUSKIEWICZ —
MICHAEL PARK —
MARK RAYDER —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2761 (119th), H.R. 5269 (119th)

Medical/Disease Research/Clinical Labs MED

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic tests.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
ALEXANDER GRAF —
JOYCE E GRESKO —
JONATHAN JAGODA —
JAMES PATRICK PALUSKIEWICZ —
MICHAEL PARK —
MARK RAYDER —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 5269 (119th), S. 2761 (119th)

Medicare/Medicaid MMM

Issues regarding prevention of antimicrobial resistance and incentives for development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
ALEXANDER GRAF —
JOYCE E GRESKO —
JONATHAN JAGODA —
JAMES PATRICK PALUSKIEWICZ —
MICHAEL PARK —
MARK RAYDER —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5269 (119th), S. 2761 (119th)

Trade (domestic/foreign) TRD

Discussions regarding tariff proposals.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
JOSEPH BODDICKER —
MARK RAYDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Pub. L. No. 119-21, One Big Beautiful Bill Act of 2025, provisions relating to Section 899 of U.S. Tax Code.

Foreign entity interest: To the extent bioMerieux, Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, bioMerieux, S.A.

LobbyistCovered position, as disclosed
JOSEPH BODDICKER —
MARK RAYDER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.